Tulynode Therapeutics is a stealth mode start up working on next gen cellular therapy targeting cancer. Our focus is to develop effective and economical therapeutic options for cancer patients. As part of that we have generated a strategy that employs novel agents, device and cellular engineering to develop cellular therapies with a potential long term, durable response in the clinic.
CART/TIL Molecular Scientist role
We are seeking a Scientist level skilled molecular scientist with CAR and/or TIL cellular engineering experience to advance our cancer immunotherapy programs, focusing on tumor infiltrating lymphocytes (TILs).
Key Responsibilities
- Isolate TILs from patient-derived tumors using different methodologies.
- Expand TIL cultures in novel-supplemented media, optimizing protocols for polyclonal activation and large-scale production while monitoring exhaustion markers.
- Engineer TILs via lentiviral transduction or CRISPR/Cas9 editing to introduce constructs, validating engineering with NGS and functional assays.
- Design and execute extensive flowcytometry marker panels, in vitro co-culture assays assessing tumor killing, cytokine secretion (IFN-γ, TNF-α), and persistence against targeting solid tumor cells.
- Collaborate with other biologists and device engineers to execute a TIL product-generating workflow, IND-enabling studies, including GLP-compliant TIL manufacturing, in vivo xenograft models, and biomarker discovery.
Required Qualifications
- PhD in Immunology, Oncology with 2+ years postdoctoral, followed by at least 2 years of industry experience in immuno-oncology, specifically associated with TIL product development.
- Experience with TIL isolation, expansion, and genetic engineering is highly desirable.
- Proven expertise in primary human T cell culture, viral vector design and production, and advanced gene editing tools is important.
- Hands-on flow cytometry proficiency (e.g., large color panels for phenotyping TIL and other lymphocyte and myeloid cell subsets) is required
- Experience with regulatory compliance (FDA/EMA) for cell therapies preferred.